HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health And Wellness Market News: Nestle Invests In Amazentis, CBD Launches, More

Executive Summary

PepsiCo promotes Steven Williams to CEO of North American division; Nestle invests in Amazentis to create supplements with its natural bioactive that improves mitochondrial function; Anlit introduces probiotic chews for women; CBD topical pain relief from Omax; more news.

You may also be interested in...



Swiss Firm Amazentis' Supplement With Urolithin A For Age-Related Muscle Decline Debuts In US

Nestle-backed Amazentis says clinical studies show its Timeline Cellular Nutrition delivers “significant” improvement in muscle strength after four months and delivers six times more urolithin A than pomegranate juice. Direct-to-consumer sales currently are available only in the US.

Functional Beverage Brands Mark Soda Giants' Footprint In Healthy Future

Dr. Pepper Snapple and PepsiCo purchase functional beverage brands Bai Brands and KeVita, respectively, to position for growth in the booming healthy drink segment, which is outpacing soda sales growth.

How China Inc. Aims To Take Over Cell Therapy Dominance

Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.

Related Companies

UsernamePublicRestriction

Register

LL1131561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel